CDXC ChromaDex Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CDXC

Price (delayed)

$3.07

Market cap

$231.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.05

Enterprise value

$207.57M

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create ...

Highlights
The company's net income has surged by 67% YoY and by 29% QoQ
The company's EPS has surged by 67% YoY and by 29% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://chromadex.com/default.aspx
Peers: NAII SGMO EXEL

Key stats

What are the main financial stats of CDXC
Market
Shares outstanding
75.54M
Market cap
$231.9M
Enterprise value
$207.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.99
Price to sales (P/S)
2.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.5
Earnings
Revenue
$83.17M
EBIT
-$3.46M
EBITDA
-$1.81M
Free cash flow
$4.53M
Per share
EPS
-$0.05
Free cash flow per share
$0.06
Book value per share
$0.38
Revenue per share
$1.11
TBVPS
$0.71
Balance sheet
Total assets
$54.08M
Total liabilities
$25.13M
Debt
$3.23M
Equity
$28.95M
Working capital
$29.52M
Liquidity
Debt to equity
0.11
Current ratio
2.52
Quick ratio
1.76
Net debt/EBITDA
13.47
Margins
EBITDA margin
-2.2%
Gross margin
61%
Net margin
-4.2%
Operating margin
-5.2%
Efficiency
Return on assets
-6.5%
Return on equity
-12.6%
Return on invested capital
-33.6%
Return on capital employed
-10%
Return on sales
-4.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDXC stock price

How has the ChromaDex stock price performed over time
Intraday
-3.76%
1 week
10.83%
1 month
14.98%
1 year
90.68%
YTD
114.69%
QTD
12.45%

Financial performance

How have ChromaDex's revenue and profit performed over time
Revenue
$83.17M
Gross profit
$50.72M
Operating income
-$4.36M
Net income
-$3.53M
Gross margin
61%
Net margin
-4.2%
ChromaDex's net margin has soared by 70% YoY and by 29% from the previous quarter
CDXC's operating margin has surged by 69% year-on-year and by 22% since the previous quarter
The company's net income has surged by 67% YoY and by 29% QoQ
ChromaDex's operating income has surged by 66% YoY and by 22% QoQ

Growth

What is ChromaDex's growth rate over time

Valuation

What is ChromaDex stock price valuation
P/E
N/A
P/B
7.99
P/S
2.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.5
The company's EPS has surged by 67% YoY and by 29% QoQ
CDXC's price to book (P/B) is 57% higher than its last 4 quarters average of 5.3 but 9% lower than its 5-year quarterly average of 9.1
The equity rose by 3.3% year-on-year
CDXC's price to sales (P/S) is 61% higher than its last 4 quarters average of 1.8 but 28% lower than its 5-year quarterly average of 4.0
The revenue has grown by 8% YoY

Efficiency

How efficient is ChromaDex business performance
The company's return on equity has surged by 71% YoY and by 29% QoQ
The company's return on sales has surged by 70% YoY and by 29% QoQ
ChromaDex's return on assets has surged by 70% YoY and by 29% QoQ
CDXC's return on invested capital is up by 45% year-on-year and by 20% since the previous quarter

Dividends

What is CDXC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDXC.

Financial health

How did ChromaDex financials performed over time
The total assets is 115% more than the total liabilities
CDXC's quick ratio is up by 11% since the previous quarter
The current ratio has increased by 5% since the previous quarter
ChromaDex's debt is 89% less than its equity
CDXC's debt to equity is down by 27% year-on-year and by 8% since the previous quarter
ChromaDex's debt has decreased by 21% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.